Xenetic Biosciences Inc. (XBIO) is a biopharmaceutical company headquartered in Framingham, Massachusetts, that focuses on the development of novel oncology therapeutics. Known for its emphasis on research and development, XBIO aims to utilize its proprietary drug technology platforms to build a diverse pipeline of novel drug candidates.
Founded in 2011, the industry-leading company continually pushes the boundaries of science by leveraging its proprietary drug delivery systems PolyXen and Virexxa. PolyXen allows for the development of next-generation biologic drugs by enhancing biological half-life, stability, and immunologic characteristics. On the other hand, Virexxa is a high-potency small molecule drug used in the treatment of severe and persistent gynaecological conditions
Xenetic Biosciences’ commitment to innovation is evident in its impressive pipeline. One example is its leading program XBIO-101 (sodium cridanimod), which showed promising results for the treatment of progesterone-resistant endometrial cancer. This oncology drug candidate has been granted orphan drug designation by the FDA, demonstrating its potential value in battling such a devastating disease.
However, their work doesn’t stop there. Beyond XBIO-101, Xenetic is leveraging its cytrowser technology to develop XBIO-201, a polysialylated form of erythropoietin for patients suffering from anemia in chronic kidney disease. This indicates the company’s interest in targeting a broad range of unmet medical needs and its commitment to improving the lives of those with difficult-to-treat diseases.
In their pursuit of creating impactful drugs, XBIO has established important collaborations with renowned organizations, such as Takeda Pharmaceuticals Co. Ltd., Serum Institute of India Limited, and SynBio LLC, thus enabling its innovative technology platform to reach its fullest potential.
Xenetic Biosciences has made impressive strides, yet, it maintains a full throttle approach to improving its platform technologies and expanding its product portfolio. They are a company that promises to keep innovating healthcare, ensuring growth while enhancing the lives of patients globally. The successful track record of XBIO and the vast unexploited potential of its technology puts it in an enviable position in the biopharmaceutical industry. It is a company that, true to its mission, seeks to answer unmet medical needs with courage, hard work, and integrity.